UNC alum, pharmaceutical exec Fred Eshelman makes another investment: experimental cancer treatment

Posted Apr 28, 2015
Fred Eshelman made another move by joining a group that invested $28 million in Innocrin Pharmaceuticals, a company developing treatments for breast and prostate cancers. Eshelman, who recently founded Eshelman Ventures, also joined Innocrin's board. (Triangle Business Journal)

Related: Campus Connections

Judge Acquits UNC Campus Shooter After Experts Agree on Tailei Qi’s Insanity
Roughly 37 months after a campus shooting left a UNC professor dead and the university community shaken, the suspect in the case is acquitted from...
Mon Sep 21, 2026

UNC School of Education builds pre-K toolkit
The free web-based guide for caregivers of young children in Person County helps bridge gaps in readiness with helpful information about kindergarten readiness and tips...
Sun Sep 20, 2026

The PlayMakers Repertory Company at UNC celebrates 50th anniversary
For 50 years, the PlayMakers Repertory Company has operated at the intersection of professional theater and college education, bringing high-level performances and world-class theater to...
Sun Sep 20, 2026

UNC alumnae lead cheers in Carolina Hurricanes’ Canes Crew
UNC alumni Maya Lin ’23 and Camryn Tuttle ’26 are part of the Carolina Hurricanes’ Canes Crew that makes the Lenovo Center “the loudest house...
Wed Sep 16, 2026